

Marta Schirripa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1588775/publications.pdf>

Version: 2024-02-01

298
papers

23,440
citations

25423

59
h-index

10129

145
g-index

300
all docs

300
docs citations

300
times ranked

27810
citing authors

#	ARTICLE	IF	CITATIONS
1	Impacts of the SARS-CoV-2 Pandemic on Young Adult Colorectal Cancer Survivors. Journal of Adolescent and Young Adult Oncology, 2022, 11, 229-233.	0.7	9
2	Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. International Journal of Cancer, 2022, 150, 279-289.	2.3	8
3	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. Journal of the National Cancer Institute, 2022, 114, 271-279.	3.0	27
4	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of the National Cancer Institute, 2022, 114, 427-435.	3.0	24
5	Reprogramming CBX8-PRC1 function with a positive allosteric modulator. Cell Chemical Biology, 2022, 29, 555-571.e11.	2.5	12
6	Association of Homologous Recombination DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. Molecular Cancer Therapeutics, 2022, 21, 227-236.	1.9	4
7	Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. Oncogene, 2022, 41, 260-267.	2.6	7
8	LRP1B and GRM3 expression in colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 177-177.	0.8	0
9	A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC).. Journal of Clinical Oncology, 2022, 40, 100-100.	0.8	3
10	Identification and characterization of recurrent neoantigens in upper gastrointestinal (GI) cancers.. Journal of Clinical Oncology, 2022, 40, 246-246.	0.8	0
11	Fertility Preservation Discussions Between Young Adult Rectal Cancer Survivors and Their Providers: Sex-Specific Prevalence and Correlates. Oncologist, 2022, 27, 579-586.	1.9	11
12	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. JAMA Network Open, 2022, 5, e2149040.	2.8	48
13	Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. Oncogene, 2022, 41, 3455-3460.	2.6	19
14	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. British Journal of Cancer, 2022, 127, 957-967.	2.9	6
15	fdrci: FDR confidence interval selection and adjustment for large-scale hypothesis testing. Bioinformatics Advances, 2022, 2, .	0.9	4
16	Molecular correlates of MAEA expression in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3128-3128.	0.8	0
17	Phase 2/3, randomized, open-label study of an individualized neoantigen vaccine (self-amplifying mRNA) Tj ETQq1 1 0.784314 rgBT /Ove diagnosed metastatic colorectal cancer (GRANITE).. Journal of Clinical Oncology, 2022, 40, TPS3635-TPS3635.	0.8	2
18	Abstract 5699: Overexpression of KMT2A is associated with worse prognosis and specific immune signatures in patients with TP53-mutated hepatocellular carcinomas. Cancer Research, 2022, 82, 5699-5699.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Comprehensive profiling of clock genes expression in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3129-3129.	0.8	0
20	Characterization of TIM3 and its ligands in colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 3547-3547.	0.8	0
21	Predictive value of <i>CDC37</i> gene expression for targeted therapy in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2022, 40, 3586-3586.	0.8	0
22	Predictive value of <i>MAOB</i> gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405.. Journal of Clinical Oncology, 2022, 40, 3580-3580.	0.8	0
23	Interplay between B cell and GABA metabolism (GABAm) and association with immune evasion in breast carcinoma (BC).. Journal of Clinical Oncology, 2022, 40, 1097-1097.	0.8	0
24	The tumor microenvironment and immune infiltration landscape of <i>KRAS</i> mutant pancreatic ductal adenocarcinomas (PDAC) compared to colorectal adenocarcinomas (CRC).. Journal of Clinical Oncology, 2022, 40, 4142-4142.	0.8	2
25	CXCR4 overexpression: An indicator of poor survival and predictor of response to immunotherapy in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 3546-3546.	0.8	2
26	Comprehensive characterization of <i>PTPRT</i> expression in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3538-3538.	0.8	0
27	Multicenter phase Ib trial in the U.S. of salvage CT041 CLDN18.2-specific chimeric antigen receptor T-cell therapy for patients with advanced gastric and pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, 2538-2538.	0.8	9
28	Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2022, 40, 3553-3553.	0.8	0
29	The differential response to immune checkpoint inhibitors in colorectal and endometrial cancer patients according to different mismatch repair alterations.. Journal of Clinical Oncology, 2022, 40, 3625-3625.	0.8	1
30	<i>DEFB1</i> gene expression and the molecular landscape of colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3523-3523.	0.8	0
31	Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): An ARCAD database analysis.. Journal of Clinical Oncology, 2022, 40, 3572-3572.	0.8	1
32	Claudin 18 (<i>CLDN18</i>) gene expression and related molecular profile in gastric cancer (GC).. Journal of Clinical Oncology, 2022, 40, 4048-4048.	0.8	1
33	Landscape of endocytosis pathway in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3148-3148.	0.8	0
34	The prognostic significance of <i>TP53</i> mutations in patients with right-sided and left-sided colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 3589-3589.	0.8	0
35	Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.. Journal of Clinical Oncology, 2022, 40, 3510-3510.	0.8	13
36	Comprehensive genomic and transcriptomic characterization of small bowel adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, 4018-4018.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Characterization of <i>NY-ESO-1</i> gene expression in gastric cancer (GC).. Journal of Clinical Oncology, 2022, 40, 4046-4046.	0.8	0
38	The Emergence of Baricitinib: A Story of Tortoises Versus Hares. Clinical Infectious Diseases, 2021, 72, 1251-1252.	2.9	5
39	Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clinical Cancer Research, 2021, 27, 1174-1183.	3.2	28
40	Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. Clinical Colorectal Cancer, 2021, 20, 84-95.e8.	1.0	15
41	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clinical Cancer Research, 2021, 27, 267-275.	3.2	13
42	Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. Investigational New Drugs, 2021, 39, 812-820.	1.2	12
43	Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. Clinical Cancer Research, 2021, 27, 2723-2733.	3.2	33
44	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. Pharmacogenomics Journal, 2021, 21, 285-295.	0.9	3
45	Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes. Scientific Reports, 2021, 11, 5639.	1.6	1
46	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. Molecular Cancer Therapeutics, 2021, 20, 1153-1160.	1.9	1
47	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 3234-3242.	3.2	24
48	Clocking cancer: the circadian clock as a target in cancer therapy. Oncogene, 2021, 40, 3187-3200.	2.6	41
49	The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. Targeted Oncology, 2021, 16, 517-527.	1.7	7
50	Single cell RNA-sequence analysis to identify transcriptomic differences associated with treatment outcome and ethnicity in circulating tumor cells (CTCs) from patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2021, 39, 3041-3041.	0.8	1
51	Human colorectal cancer-on-chip model to study the microenvironmental influence on early metastatic spread. IScience, 2021, 24, 102509.	1.9	33
52	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. Scientific Reports, 2021, 11, 12191.	1.6	3
53	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. European Journal of Cancer, 2021, 150, 133-142.	1.3	1
54	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Oncogene, 2021, 40, 4894-4905.	2.6	19

#	ARTICLE	IF	CITATIONS
55	VprBP directs epigenetic gene silencing through histone H2A phosphorylation in colon cancer. <i>Molecular Oncology</i> , 2021, 15, 2801-2817.	2.1	14
56	Evaluating the impact of age on immune checkpoint therapy biomarkers. <i>Cell Reports</i> , 2021, 36, 109599.	2.9	27
57	Microsatellite Stable Colorectal Liver Metastases—Understanding the Mechanisms of Immune Resistance. <i>JAMA Network Open</i> , 2021, 4, e2119025.	2.8	4
58	Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy. <i>Journal of Controlled Release</i> , 2021, 336, 433-442.	4.8	4
59	Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931). <i>Cancer</i> , 2021, 127, 3801-3808.	2.0	6
60	Clinical Significance of Circulating Tumor Cell Induced Epithelial-Mesenchymal Transition in Patients with Metastatic Colorectal Cancer by Single-Cell RNA-Sequencing. <i>Cancers</i> , 2021, 13, 4862.	1.7	8
61	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 155, 73-84.	1.3	13
62	Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 317-324.	1.0	4
63	Molecular characterization of squamous cell carcinoma of the anal canal. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2423-2437.	0.6	7
64	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , 2021, 5, 95.	2.3	9
65	Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2021, , .	2.9	1
66	Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 10-16.	0.7	2
67	Imaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response. <i>Frontiers in Oncology</i> , 2021, 11, 771173.	1.3	9
68	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 846-854.	3.2	90
69	Partition: a surjective mapping approach for dimensionality reduction. <i>Bioinformatics</i> , 2020, 36, 676-681.	1.8	6
70	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 404-413.	1.9	25
71	Cumulative Burden of Colorectal Cancer—Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. <i>Gastroenterology</i> , 2020, 158, 1274-1286.e12.	0.6	110
72	Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. <i>Molecular Therapy</i> , 2020, 28, 536-547.	3.7	135

#	ARTICLE	IF	CITATIONS
73	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. <i>European Journal of Cancer</i> , 2020, 140, 119-129.	1.3	37
74	Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. <i>Cancers</i> , 2020, 12, 2947.	1.7	4
75	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. <i>PLoS ONE</i> , 2020, 15, e0239439.	1.1	5
76	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2634-2640.	1.9	14
77	All You Need to Know About <i>DPYD</i> Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide. <i>JCO Oncology Practice</i> , 2020, 16, 793-798.	1.4	46
78	Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. <i>ESMO Open</i> , 2020, 5, e000942.	2.0	26
79	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. , 2020, 8, e001714.		23
80	The structure-function relationship of oncogenic LMTK3. <i>Science Advances</i> , 2020, 6, .	4.7	18
81	Risk of Persistent Opioid Use following Major Surgery in Matched Samples of Patients with and without Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2126-2133.	1.1	7
82	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Clinical Cancer Research</i> , 2020, 26, 5943-5951.	3.2	55
83	Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1713.	3.4	24
84	Novel Genomic Differences in Cell-Free Circulating DNA Profiles of Young- Versus Older-Onset Colorectal Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 10, 336-341.	0.7	2
85	Anti-EGFR Therapy Induces EGF Secretion by Cancer-Associated Fibroblasts to Confer Colorectal Cancer Chemoresistance. <i>Cancers</i> , 2020, 12, 1393.	1.7	38
86	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. , 2020, 8, e000404.		29
87	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020, 12, 1319.	1.7	10
88	Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases. <i>Science Advances</i> , 2020, 6, eaba6752.	4.7	24
89	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. <i>Scientific Reports</i> , 2020, 10, 9778.	1.6	5
90	12â€Chemokine signature, a predictor of tumor recurrence in colorectal cancer. <i>International Journal of Cancer</i> , 2020, 147, 532-541.	2.3	39

#	ARTICLE	IF	CITATIONS
91	Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2020, 121, 1320-1328.	0.8	16
92	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , 2020, 5, e000682.	2.0	64
93	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€“Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	12.5	218
94	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. <i>Cancers</i> , 2020, 12, 1742.	1.7	4
95	Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome. <i>Clinical Cancer Research</i> , 2020, 26, 4756-4766.	3.2	7
96	Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. <i>Cancer Science</i> , 2020, 111, 441-450.	1.7	8
97	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , 2020, 46, 955-966.	0.5	22
98	The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. <i>Cancer Cell International</i> , 2020, 20, 30.	1.8	63
99	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2020, 131, 89-97.	1.3	9
100	Relationship between <scp>MLH1</scp>, <scp>PMS2</scp>, <scp>MSH2</scp> and <scp>MSH6</scp> geneâ€“specific alterations and tumor mutational burden in 1057 microsatellite instabilityâ€“high solid tumors. <i>International Journal of Cancer</i> , 2020, 147, 2948-2956.	2.3	102
101	Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. <i>European Journal of Cancer</i> , 2020, 133, 66-73.	1.3	19
102	Comprehensive molecular analysis of microsatellite-stable (MSS) tumors with high mutational burden in gastrointestinal (GI) cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3631-3631.	0.8	0
103	Molecular correlates of PD-L1 expression in patients (pts) with gastroesophageal (GE) cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4558-4558.	0.8	0
104	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. <i>Oncologist</i> , 2019, 24, 319-326.	1.9	29
105	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the â€“BRAF BeCoolâ€“™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	1.3	51
106	High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma. <i>PLoS ONE</i> , 2019, 14, e0219469.	1.1	8
107	Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. <i>EBioMedicine</i> , 2019, 45, 139-154.	2.7	36
108	<p>The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer<p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 5911-5924.	0.9	25

#	ARTICLE	IF	CITATIONS
109	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , 2019, 20, 1070-1082.	5.1	169
110	Molecular insight of regorafenib treatment for colorectal cancer. <i>Cancer Treatment Reviews</i> , 2019, 81, 101912.	3.4	109
111	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2019, 25, 7497-7505.	3.2	44
112	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
113	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3096-3103.	3.2	65
114	Quantitative evidence for early metastatic seeding in colorectal cancer. <i>Nature Genetics</i> , 2019, 51, 1113-1122.	9.4	315
115	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 305-343.	157.7	203
116	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. <i>European Journal of Cancer</i> , 2019, 111, 138-147.	1.3	4
117	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. <i>International Journal of Cancer</i> , 2019, 145, 2082-2090.	2.3	4
118	A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2019, 145, 2450-2458.	2.3	5
119	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019, 4, e000489.	2.0	14
120	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019, 109, 175-182.	1.3	25
121	A Multicenter Comparison of Complementary and Alternative Medicine (CAM) Discussions in Oncology Care: The Role of Time, Patient-Centeredness, and Practice Context. <i>Oncologist</i> , 2019, 24, e1180-e1189.	1.9	17
122	Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). <i>Oncologist</i> , 2019, 24, 921-932.	1.9	51
123	MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2988-2995.	3.2	42
124	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2019, 18, e8-e19.	1.0	12
125	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. <i>European Journal of Cancer</i> , 2019, 107, 100-114.	1.3	12
126	Genetic variants in <i>CCL5</i> and <i>CCR5</i> genes and serum VEGF levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. <i>International Journal of Cancer</i> , 2019, 144, 2567-2577.	2.3	8

#	ARTICLE	IF	CITATIONS
127	B cell and B cell-related pathways for novel cancer treatments. <i>Cancer Treatment Reviews</i> , 2019, 73, 10-19.	3.4	132
128	Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer. <i>Oncotarget</i> , 2019, 10, 7016-7030.	0.8	10
129	Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 564-564.	0.8	0
130	Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3048-3048.	0.8	1
131	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. <i>Molecular Cancer Research</i> , 2018, 16, 805-812.	1.5	169
132	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e471-e488.	1.0	12
133	Outlooks on Epstein-Barr virus associated gastric cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 15-22.	3.4	149
134	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 251-266.	1.1	41
135	Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. <i>Biochemical and Biophysical Research Communications</i> , 2018, 500, 621-625.	1.0	44
136	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Handâ€™Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Clinical Colorectal Cancer</i> , 2018, 17, e395-e414.	1.0	25
137	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 118, 938-946.	2.9	29
138	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018, 118, 955-965.	2.9	17
139	Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients. <i>Pharmacogenomics Journal</i> , 2018, 18, 29-34.	0.9	38
140	Biomarker-driven and molecular targeted therapies for colorectal cancers. <i>Seminars in Oncology</i> , 2018, 45, 124-132.	0.8	9
141	CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation â€™ A target for novel cancer therapy. <i>Cancer Treatment Reviews</i> , 2018, 63, 40-47.	3.4	867
142	Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. <i>Clinical Colorectal Cancer</i> , 2018, 17, e121-e125.	1.0	19
143	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. <i>Cancer Treatment Reviews</i> , 2018, 63, 48-60.	3.4	134
144	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. <i>Clinical Cancer Research</i> , 2018, 24, 784-793.	3.2	23

#	ARTICLE	IF	CITATIONS
145	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 773-779.	0.8	1,525
146	Practice-changing updates in the adjuvant and metastatic setting. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 77-78.	12.5	29
147	Reprogramming Exosomes as Nanoscale Controllers of Cellular Immunity. <i>Journal of the American Chemical Society</i> , 2018, 140, 16413-16417.	6.6	195
148	Management of Advanced Small Bowel Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 69.	1.3	25
149	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1451-1455.	2.9	19
150	Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2788-2795.	1.9	4
151	A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1193-1198.	0.6	21
152	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2018, 18, 623-632.	0.9	8
153	Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. <i>Cancer Cell International</i> , 2018, 18, 99.	1.8	48
154	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2018, 18, 98.	1.1	17
155	Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e741-e749.	1.0	20
156	Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. <i>Oncologist</i> , 2018, 23, 1319-1327.	1.9	131
157	Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2018, 24, 4734-4744.	3.2	14
158	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. <i>PLoS ONE</i> , 2018, 13, e0193640.	1.1	5
159	Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, 215-222.e3.	1.0	4
160	Circadian clock gene PER1 mutations in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12106-12106.	0.8	2
161	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3576-3576.	0.8	2
162	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. <i>Journal of Cancer Metastasis and Treatment</i> , 2018, 4, 12.	0.5	5

#	ARTICLE	IF	CITATIONS
163	Genetic variants within the glucocorticoids related genes to predict outcome in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 12098-12098.	0.8	0
164	Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).. Journal of Clinical Oncology, 2018, 36, 4098-4098.	0.8	0
165	The role of pharmacogenetics in the new ESMO colorectal cancer guidelines. Pharmacogenomics, 2017, 18, 197-200.	0.6	7
166	Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Annals of Oncology, 2017, 28, 1015-1022.	0.6	24
167	What We Know About Stage II and III Colon Cancer: It's Still Not Enough. Targeted Oncology, 2017, 12, 265-275.	1.7	25
168	VEGF Ligands. , 2017, , 639-658.		0
169	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 2392.	3.8	670
170	Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. International Journal of Cancer, 2017, 141, 1222-1230.	2.3	21
171	Single nucleotide polymorphisms in the IGF1RS pathway are associated with outcome in mCRC patients enrolled in the FIRE3 trial. International Journal of Cancer, 2017, 141, 383-392.	2.3	10
172	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. European Journal of Cancer, 2017, 77, 13-20.	1.3	19
173	Potential role of polymorphisms in the transporter genes ENT1 and MATE1 / OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. European Journal of Cancer, 2017, 86, 197-206.	1.3	22
174	Colorectal cancer: epigenetic alterations and their clinical implications. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 439-448.	3.3	48
175	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncology, The, 2017, 18, 1182-1191.	5.1	2,058
176	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Cancer, 2017, 123, 4506-4514.	2.0	8
177	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. Expert Opinion on Biological Therapy, 2017, 17, 1297-1308.	1.4	21
178	Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Annals of Oncology, 2017, 28, 2780-2785.	0.6	28
179	DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer. Cancer, 2017, 123, 3732-3743.	2.0	19
180	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. BMC Cancer, 2017, 17, 408.	1.1	28

#	ARTICLE	IF	CITATIONS
181	Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. Indian Journal of Surgical Oncology, 2017, 8, 580-590.	0.3	2
182	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. JAMA Oncology, 2017, 3, 194.	3.4	555
183	Immunotherapy in Gastrointestinal Cancers. BioMed Research International, 2017, 2017, 1-17.	0.9	69
184	Genetic variations within the vitamin C transporter genes to predict outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.. Journal of Clinical Oncology, 2017, 35, 11507-11507.	0.8	1
185	Characterization of tumor mutation load (TML) in solid tumors.. Journal of Clinical Oncology, 2017, 35, 11517-11517.	0.8	19
186	Association of immune-related genes to neutrophil-lymphocyte ratio (NLR) with survival of cetuximab treatment for metastatic colorectal cancer (mCRC): JACCRO CC-05/06AR.. Journal of Clinical Oncology, 2017, 35, 11613-11613.	0.8	1
187	Primary (1 ^o) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2017, 35, 3503-3503.	0.8	49
188	Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).. Journal of Clinical Oncology, 2017, 35, 3505-3505.	0.8	42
189	Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.. Journal of Clinical Oncology, 2017, 35, 3510-3510.	0.8	34
190	Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.. Journal of Clinical Oncology, 2017, 35, 3531-3531.	0.8	26
191	Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.. Journal of Clinical Oncology, 2017, 35, 519-519.	0.8	49
192	Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary (1 ^o) tumor side.. Journal of Clinical Oncology, 2017, 35, 3528-3528.	0.8	1
193	New perspectives for colorectal cancer. Oncotarget, 2017, 8, 41782-41783.	0.8	0
194	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	2.0	82
195	Tandem repeat variation in HIC1 gene predicts outcome for oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, vi38.	0.6	0
196	Biomarker in Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 156-164.	1.0	35
197	The safety of monoclonal antibodies for treatment of colorectal cancer. Expert Opinion on Drug Safety, 2016, 15, 799-808.	1.0	24
198	Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. Expert Review of Clinical Pharmacology, 2016, 9, 1091-1108.	1.3	9

#	ARTICLE	IF	CITATIONS
199	Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2016, 17, 751-759.	1.5	14
200	Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2814-2821.	1.9	9
201	An Open-Label, Dose- Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 5204-5210.	3.2	19
202	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO. <i>Annals of Oncology</i> , 2016, 27, vi152.	0.6	3
203	Molecular Pathways: Cachexia Signaling- A Targeted Approach to Cancer Treatment. <i>Clinical Cancer Research</i> , 2016, 22, 3999-4004.	3.2	85
204	Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1740-1745.	1.9	9
205	Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population. <i>Clinical Colorectal Cancer</i> , 2016, 15, e221-e227.	1.0	9
206	CDX2 as a Prognostic Biomarker in Colon Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 2182-2184.	13.9	23
207	A novel antimetabolite: TAS-102 for metastatic colorectal cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 355-365.	1.3	11
208	TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1405-1411.	1.9	11
209	Overcoming resistance to anti-EGFR therapy - where do we stand?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 258-259.	8.2	10
210	Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 117-126.	2.0	1
211	Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 3218-3226.	3.2	21
212	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 30-36.	2.9	56
213	MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3515-3515.	0.8	5
214	MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 493-493.	0.8	15
215	Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. <i>Oncotarget</i> , 2016, 7, 53668-53678.	0.8	26
216	TAS-102, a novel antitumor agent: A review of the mechanism of action. <i>Cancer Treatment Reviews</i> , 2015, 41, 777-783.	3.4	115

#	ARTICLE	IF	CITATIONS
217	Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. <i>Cancer</i> , 2015, 121, 1898-1905.	2.0	12
218	P-198 Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib. <i>Annals of Oncology</i> , 2015, 26, iv57.	0.6	1
219	Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. <i>Annals of Oncology</i> , 2015, 26, 724-730.	0.6	136
220	Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	385
221	Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and <i>RAS</i> Mutations in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 692-700.	0.8	686
222	First-line chemotherapy for mCRC—a review and evidence-based algorithm. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 607-619.	12.5	138
223	Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2401-2408.	1.9	25
224	Non-coding RNAs derived from an alternatively spliced REST transcript (REST-003) regulate breast cancer invasiveness. <i>Scientific Reports</i> , 2015, 5, 11207.	1.6	26
225	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology</i> , The, 2015, 16, 937-948.	5.1	286
226	IL-33 activates tumor stroma to promote intestinal polyposis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2487-96.	3.3	141
227	Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 1551-1556.	0.8	110
228	The Molecular Taxonomy of Colorectal Cancer: What's New?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 118-124.	1.0	2
229	Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1909-1919.	13.9	1,027
230	BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. <i>British Journal of Cancer</i> , 2015, 112, 1921-1928.	2.9	146
231	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2374-2381.	1.9	4
232	Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 897-907.	1.1	27
233	TAS-102 for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1283-1292.	1.1	12
234	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 2503.	0.6	18

#	ARTICLE	IF	CITATIONS
235	Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor. <i>Clinical Cancer Research</i> , 2015, 21, 5002-5007.	3.2	61
236	Predictive and Prognostic Markers in the Treatment of Metastatic Colorectal Cancer (mCRC). <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 43-60.	0.9	24
237	Role of <i>NRAS</i> mutations as prognostic and predictive markers in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2015, 136, 83-90.	2.3	126
238	Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the phase 3 RECURSE trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2579-2579.	0.8	10
239	DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3532-3532.	0.8	2
240	LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS794-TPS794.	0.8	2
241	The Kinase LMTK3 Promotes Invasion in Breast Cancer Through GRB2-Mediated Induction of Integrin $\beta 1$. <i>Science Signaling</i> , 2014, 7, ra58.	1.6	32
242	Prospective study of EGFR intron 1 (CA) _n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. <i>Pharmacogenomics Journal</i> , 2014, 14, 322-327.	0.9	11
243	Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 528-539.	1.9	37
244	ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer. <i>Cell Reports</i> , 2014, 7, 1940-1955.	2.9	90
245	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. <i>Targeted Oncology</i> , 2014, 9, 205-214.	1.7	27
246	Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 282-298.	12.5	312
247	Molecular Pathways: Turning Proteasomal Protein Degradation into a Unique Treatment Approach. <i>Clinical Cancer Research</i> , 2014, 20, 3064-3070.	3.2	13
248	FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2014, 50, 57-63.	1.3	162
249	So Much Effort, So Little Progress?. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	5
250	A <i>let-7</i> microRNA-Binding Site Polymorphism in <i>KRAS</i> Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy. <i>Clinical Cancer Research</i> , 2014, 20, 4499-4510.	3.2	55
251	Correlation of anti-calreticulin antibody titers with improved overall survival in a phase 2 clinical trial of algenpantucel-L immunotherapy for patients with resected pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3029-3029.	0.8	4
252	Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3505-3505.	0.8	41

#	ARTICLE	IF	CITATIONS
253	Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.. Journal of Clinical Oncology, 2014, 32, 3506-3506.	0.8	40
254	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).. Journal of Clinical Oncology, 2014, 32, LBA3-LBA3.	0.8	68
255	Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study.. Journal of Clinical Oncology, 2014, 32, LBA444-LBA444.	0.8	26
256	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 303-312.	6.3	2,276
257	Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. British Journal of Cancer, 2013, 108, 2549-2556.	2.9	51
258	Markers of Response for the Antiangiogenic Agent Bevacizumab. Journal of Clinical Oncology, 2013, 31, 1219-1230.	0.8	309
259	FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS,) Tj ETQq1 1 0.784314 rgBT /Overl... Nord Ovest (GONO). Annals of Oncology, 2013, 24, 2062-2067.	0.6	86
260	Molecular Pathways: Estrogen Pathway in Colorectal Cancer. Clinical Cancer Research, 2013, 19, 5842-5848.	3.2	181
261	Reply: Comment on "Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab". British Journal of Cancer, 2013, 109, 3129-3130.	2.9	3
262	Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. PLoS ONE, 2013, 8, e66774.	1.1	64
263	Time course of regorafenib-associated adverse events in the phase III CORRECT study.. Journal of Clinical Oncology, 2013, 31, 467-467.	0.8	15
264	Pharmacogenomics and metastatic colorectal cancer: Current knowledge and perspectives. Scandinavian Journal of Gastroenterology, 2012, 47, 325-339.	0.6	11
265	EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. Annals of Oncology, 2012, 23, 1370-1371.	0.6	7
266	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Annals of Oncology, 2012, 23, 1207-1213.	0.6	40
267	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. Current Colorectal Cancer Reports, 2012, 8, 153-160.	1.0	0
268	Pharmacogenetic Concerns in Metastatic Colorectal Cancer Therapy. Current Colorectal Cancer Reports, 2012, 8, 263-271.	1.0	1
269	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer. Cancer, 2012, 118, 1523-1532.	2.0	34
270	MAVERICC: A randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV with prospective biomarker stratification in previously untreated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2012, 30, TPS3635-TPS3635.	0.8	1

#	ARTICLE	IF	CITATIONS
271	Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET).. Journal of Clinical Oncology, 2012, 30, 260-260.	0.8	7
272	Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.. Journal of Clinical Oncology, 2012, 30, LBA385-LBA385.	0.8	34
273	Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2011, 17, 5783-5792.	3.2	79
274	Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. Expert Opinion on Biological Therapy, 2011, 11, 519-531.	1.4	3
275	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer, 2011, 11, 247.	1.1	69
276	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. British Journal of Cancer, 2011, 104, 1262-1269.	2.9	85
277	Using The Colon Cancer Multigene Recurrence Score to Determine Risk: Prognostic Milestone or a Step in the Right Direction?. Current Colorectal Cancer Reports, 2010, 6, 183-192.	1.0	0
278	Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type <i>KRAS</i> mCRC Patients. Clinical Cancer Research, 2010, 16, 5591-5602.	3.2	43
279	Colorectal cancer. Lancet, The, 2010, 375, 1030-1047.	6.3	1,318
280	Gender Disparities in Metastatic Colorectal Cancer Survival. Clinical Cancer Research, 2009, 15, 6391-6397.	3.2	168
281	Can we predict the response to epidermal growth factor receptor targeted therapy?. Targeted Oncology, 2008, 3, 87-99.	1.7	1
282	Individualization of therapy based on clinical and molecular parameters. Current Colorectal Cancer Reports, 2008, 4, 193-200.	1.0	3
283	First-line combination treatment of colorectal cancer with hepatic metastases: Choosing a targeted agent. Cancer Treatment Reviews, 2008, 34, S3-S7.	3.4	77
284	Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab. Clinical Cancer Research, 2008, 14, 7554-7563.	3.2	179
285	Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab. Clinical Cancer Research, 2008, 14, 7884-7895.	3.2	116
286	KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors. Clinical Advances in Hematology and Oncology, 2008, 6, 1-13, 14-6.	0.3	0
287	The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer. Oncologist, 2007, 12, 38-50.	1.9	218
288	FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab. Journal of Clinical Oncology, 2007, 25, 3712-3718.	0.8	466

#	ARTICLE	IF	CITATIONS
289	Cetuximab in the management of colorectal cancer. <i>Biologics: Targets and Therapy</i> , 2007, 1, 77-91.	3.0	13
290	Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 475-483.	0.7	97
291	Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines. <i>Journal of Clinical Oncology</i> , 2006, 24, 4914-4921.	0.8	504
292	Pharmacogenomics and Colorectal Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2006, 587, 211-231.	0.8	26
293	A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 319-327.	5.7	285
294	Implications of Genetic Testing in the Management of Colorectal Cancer. <i>Molecular Diagnosis and Therapy</i> , 2003, 3, 73-88.	3.3	13
295	ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 162-6.	0.3	108
296	ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy. <i>Journal of Clinical Oncology</i> , 2001, 19, 4298-4304.	0.8	601
297	Determinants of prognosis and response to therapy in colorectal cancer. <i>Current Oncology Reports</i> , 2001, 3, 102-108.	1.8	35
298	High frequency of simultaneous loss of p16 and p16 ^{ink4} gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach. <i>Oncogene</i> , 1997, 15, 1481-1488.	2.6	23